Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Stock Chart & Stats
$10.66
-$0.28(-2.38%)
At close: 4:00 PM EST
$10.66
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $13.33
Previous CloseN/A
Volume73.34K
Average Volume (3M)959.24K
Market Cap
$642.16M
Enterprise Value$18.91M
Total Cash (Recent Filing)$332.60M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 05, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding59,076,260
10 Day Avg. Volume652,199
30 Day Avg. Volume959,242
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market Cap0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-248.77
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$31.71Price Target Upside197.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.03
Revenue Forecast (FY)$24.59M
Bulls Say, Bears Say
Bulls Say
CLN-049 Efficacy And DevelopmentClinical data indicating meaningful complete responses and a manageable safety profile for CLN-049 support its potential as a broadly applicable AML therapy and underpin plans for pivotal and frontline combination studies.
Pipeline DiversificationCullinan's broad pipeline spanning autoimmune and oncology programs, including CLN-978 and CLN-049, offers multiple independent development avenues that could boost company value if several programs advance.
Zipalertinib Regulatory And Commercial OpportunityCompletion of the rolling NDA submission for zipalertinib, combined with an option to co-commercialize in the U.S., could lead to regulatory approval and commercial upside through partnership arrangements.
Bears Say
Competitive Data RiskSuperior efficacy results from competing programs in overlapping indications could shrink the addressable market and undermine enthusiasm for the company's candidates.
Financing And Dilution RiskParallel advancement of multiple programs may require additional capital raises that could dilute existing shareholders and pressure the stock.
Trial Enrollment RiskSlow enrollment in key studies could postpone data readouts and extend development timelines, reducing visibility into near-term program milestones.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $13.33 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $642.16M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Mar 05, 2026 which is in 48 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Nov 06, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.947 by $0.177.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.79.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 59,076,260 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.947. Following the earnings report the stock price went up 0.547%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.71 (197.47% Upside)
$31.71 (197.47% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 903.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.59%
12-Months-Change
Fundamentals
Return on Equity
-40.18%
Trailing 12-Months
Asset Growth
-25.89%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$31.71
▲(197.47% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---